- Home
- ARHS vs OCUL Comparison
ARHS vs OCUL Comparison
Compare ARHS & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- OCUL
- Stock Information
- Founded
- ARHS 1986
- OCUL 2006
- Country
- ARHS United States
- OCUL United States
- Employees
- ARHS N/A
- OCUL N/A
- Industry
- ARHS Other Specialty Stores
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- OCUL Health Care
- Exchange
- ARHS Nasdaq
- OCUL Nasdaq
- Market Cap
- ARHS 1.1B
- OCUL 957.3M
- IPO Year
- ARHS 2021
- OCUL 2014
- Fundamental
- Price
- ARHS $7.96
- OCUL $7.06
- Analyst Decision
- ARHS Buy
- OCUL Strong Buy
- Analyst Count
- ARHS 13
- OCUL 10
- Target Price
- ARHS $11.19
- OCUL $16.11
- AVG Volume (30 Days)
- ARHS 1.4M
- OCUL 1.6M
- Earning Date
- ARHS 05-08-2025
- OCUL 05-05-2025
- Dividend Yield
- ARHS N/A
- OCUL N/A
- EPS Growth
- ARHS N/A
- OCUL N/A
- EPS
- ARHS 0.41
- OCUL N/A
- Revenue
- ARHS $1,287,317,000.00
- OCUL $59,647,000.00
- Revenue This Year
- ARHS $10.22
- OCUL $13.32
- Revenue Next Year
- ARHS $8.28
- OCUL $13.13
- P/E Ratio
- ARHS $19.42
- OCUL N/A
- Revenue Growth
- ARHS 0.71
- OCUL N/A
- 52 Week Low
- ARHS $6.61
- OCUL $4.06
- 52 Week High
- ARHS $19.81
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- ARHS 45.95
- OCUL 44.18
- Support Level
- ARHS $7.80
- OCUL $6.84
- Resistance Level
- ARHS $8.52
- OCUL $8.90
- Average True Range (ATR)
- ARHS 0.41
- OCUL 0.47
- MACD
- ARHS 0.06
- OCUL -0.11
- Stochastic Oscillator
- ARHS 32.63
- OCUL 10.71
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.